text:
Tay–Sachs disease
From Wikipedia, the free encyclopedia
Jump to: navigation, search
Tay–Sachs disease
Synonyms
GM2 gangliosidosis, hexosaminidase A deficiency[1]
Cherry-red spot as seen in the retina in Tay–Sachs disease. The fovea's center appears bright red because it is surrounded by a whiter than usual area.
Specialty
Medical genetics
Symptoms
Initially: Decreased ability to turn over, sit, or crawl[1]
Later: Seizures, hearing loss, inability to move[1]
Usual onset
Three to six months of age[1]
Duration
Long term[2]
Types
Infantile, juvenile, late-onset[2]
Causes
Genetic (autosomal recessive)[1]
Diagnostic method
Testing blood hexosaminidase A levels, genetic testing[2]
Similar conditions
Sandhoff disease, Leigh syndrome, neuronal ceroid lipofuscinoses[2]
Treatment
Supportive care, psychosocial support
Prognosis
Death often occurs in early childhood[1]
Frequency
Rare in the general population[1]
[edit on Wikidata]
Tay–Sachs disease is a genetic disorder that results in the destruction of nerve cells in the brain and spinal cord.[1] The most common type, known as infantile Tay–Sachs disease, becomes apparent around three to six months of age with the baby losing the ability to turn over, sit, or crawl.[1] This is then followed by seizures, hearing loss, and inability to move.[1] Death usually occurs in early childhood.[1] Less commonly the disease may occur in later childhood or adulthood.[1] These forms are generally milder in nature.[1]
Tay–Sachs disease is caused by a genetic mutation in the HEXA genes on chromosome 15.[1] It is inherited from a person's parents in an autosomal recessive manner.[1] The mutation results in problems with an enzyme called beta-hexosaminidase A which results in the buildup of the molecule GM2 ganglioside within cells, leading to toxicity.[1] Diagnosis is by measuring the blood hexosaminidase A level or genetic testing.[2] It is a type of sphingolipidosis.[3]
The treatment of Tay–Sachs disease is supportive in nature.[2] This may involve multiple specialities as well as psychosocial support for the family.[2] The disease is rare in the general population.[1] In Ashkenazi Jews, French Canadians of southeastern Quebec, and Cajuns of southern Louisiana, the condition is more common.[2][1] Approximately 1 in 3,600 Ashkenazi Jews at birth are affected.[2]
The disease is named after Waren Tay, who in 1881 first described a symptomatic red spot on the retina of the eye; and Bernard Sachs, who described in 1887 the cellular changes and noted an increased rate of disease in Ashkenazi Jews.[4] Carriers of a single Tay–Sachs allele are typically normal.[2] It has been hypothesized that being a carrier may confer protection from another condition such as tuberculosis, explaining the persistence of the allele in certain populations.[5] Researchers are looking at gene therapy or enzyme replacement therapy as possible treatments.[2]
Contents
[hide]
1 Signs and symptoms
2 Genetics
3 Pathophysiology
4 Diagnosis
5 Prevention
6 Management
7 Outcomes
8 Epidemiology
9 History
10 Society and culture
11 Research directions
11.1 Enzyme replacement therapy
11.2 Jacob sheep model
11.3 Substrate reduction therapy
11.4 Increasing β-hexosaminidase A activity
12 References
13 External links
Signs and symptoms[edit]
Tay–Sachs disease is typically first noticed in infants around 6 months old displaying an abnormally strong response to sudden noises or other stimulus, known as the "startle response". There may also be listlessness or muscle stiffness (hypertonia). The disease is classified into several forms, which are differentiated based on the onset age of neurological symptoms.[6][7]
Infantile Tay–Sachs disease. Infants with Tay–Sachs disease appear to develop normally for the first six months after birth. Then, as neurons become distended with gangliosides, a relentless deterioration of mental and physical abilities begins. The child may become blind, deaf, unable to swallow, atrophied, and paralytic. Death usually occurs before the age of four.[6]
Juvenile Tay–Sachs disease. Juvenile Tay–Sachs disease is rarer than other forms of Tay–Sachs, and usually is initially seen in children between two and ten years old. People with Tay–Sachs disease develop cognitive and motor skill deterioration, dysarthria, dysphagia, ataxia, and spasticity.[8] Death usually occurs between the age of five to fifteen years.[9]
Adult/Late-Onset Tay–Sachs disease. A rare form of this disease, known as Adult-Onset or Late-Onset Tay–Sachs disease, usually has its first symptoms during the 30s or 40s. In contrast to the other forms, late-onset Tay–Sachs disease is usually not fatal as the effects can stop progressing. It is frequently misdiagnosed. It is characterized by unsteadiness of gait and progressive neurological deterioration. Symptoms of late-onset Tay–Sachs – which typically begin to be seen in adolescence or early adulthood – include speech and swallowing difficulties, unsteadiness of gait, spasticity, cognitive decline, and psychiatric illness, particularly a schizophrenia-like psychosis.[10] People with late-onset Tay–Sachs may become full-time wheelchair users in adulthood.
Until the 1970s and 1980s, when the disease's molecular genetics became known, the juvenile and adult forms of the disease were not always recognized as variants of Tay–Sachs disease. Post-infantile Tay–Sachs was often misdiagnosed as another neurological disorder, such as Friedreich's ataxia.[11]
Genetics[edit]
Tay–Sachs disease is inherited in the autosomal recessive pattern, depicted above.
The HEXA gene is located on the long (q) arm of human chromosome 15, between positions 23 and 24.
Tay–Sachs disease is an autosomal recessive genetic disorder, meaning that when both parents are carriers, there is a 25% risk of giving birth to an affected child with each pregnancy. The affected child would have received a mutated copy of the gene from each parent.[6]
Tay–Sachs results from mutations in the HEXA gene on chromosome 15, which encodes the alpha-subunit of beta-N-acetylhexosaminidase A, a lysosomal enzyme. By 2000, more than 100 different mutations had been identified in the human HEXA gene.[12] These mutations have included single base insertions and deletions, splice phase mutations, missense mutations, and other more complex patterns. Each of these mutations alters the gene's protein product (i.e., the enzyme), sometimes severely inhibiting its function.[13] In recent years, population studies and pedigree analysis have shown how such mutations arise and spread within small founder populations. Initial research focused on several such founder populations:
Ashkenazi Jews. A four base pair insertion in exon 11 (1278insTATC) results in an altered reading frame for the HEXA gene. This mutation is the most prevalent mutation in the Ashkenazi Jewish population, and leads to the infantile form of Tay–Sachs disease.[14]
Cajun. The same 1278insTATC mutation found among Ashkenazi Jews occurs in the Cajun population of southern Louisiana. Researchers have traced the ancestry of carriers from Louisiana families back to a single founder couple – not known to be Jewish – who lived in France in the 18th century.[15]
French Canadians. Two mutations, unrelated to the Ashkenazi/Cajun mutation, are absent in France but common among French Canadians living in eastern Quebec and Acadians from the Province of New Brunswick. Pedigree analysis suggests the mutations were uncommon before the late 17th century.[16][17]
In the 1960s and early 1970s, when the biochemical basis of Tay–Sachs disease was first becoming known, no mutations had been sequenced directly for genetic diseases. Researchers of that era did not yet know how common polymorphisms would prove to be. The "Jewish Fur Trader Hypothesis," with its implication that a single mutation must have spread from one population into another, reflected the knowledge at the time. Subsequent research, however, has proven that a large variety of different HEXA mutations can cause the disease. Because Tay–Sachs was one of the first genetic disorders for which widespread genetic screening was possible, it is one of the first genetic disorders in which the prevalence of compound heterozygosity has been demonstrated.[18]
Compound heterozygosity ultimately explains the disease's variability, including the late-onset forms. The disease can potentially result from the inheritance of two unrelated mutations in the HEXA gene, one from each parent. Classic infantile Tay–Sachs disease results when a child has inherited mutations from both parents that completely stop the biodegradation of gangliosides. Late onset forms occur due to the diverse mutation base – people with Tay–Sachs disease may technically be heterozygotes, with two differing HEXA mutations that both inactivate, alter, or inhibit enzyme activity. When a patient has at least one HEXA copy that still enables some level of hexosaminidase A activity, a later onset disease form occurs. When disease occurs because of two unrelated mutations, the patient is said to be a compound heterozygote.[19]
Heterozygous carriers (individuals who inherit one mutant allele) show abnormal enzyme activity but manifest no disease symptoms. This phenomenon is called dominance; the biochemical reason for wild-type alleles' dominance over nonfunctional mutant alleles in inborn errors of metabolism comes from how enzymes function. Enzymes are protein catalysts for chemical reactions; as catalysts, they speed up reactions without being used up in the process, so only small enzyme quantities are required to carry out a reaction. Someone homozygous for a nonfunctional mutation in the enzyme-encoding gene has little or no enzyme activity, so will manifest the abnormal phenotype. A heterozygote (heterozygous individual) has at least half of the normal enzyme activity level, due to expression of the wild-type allele. This level is normally enough to enable normal function and thus prevent phenotypic expression.[20]
Pathophysiology[edit]
Tay–Sachs disease is caused by insufficient activity of the enzyme hexosaminidase A. Hexosaminidase A is a vital hydrolytic enzyme, found in the lysosomes, that breaks down sphingolipids. When hexosaminidase A is no longer functioning properly, the lipids accumulate in the brain and interfere with normal biological processes. Hexosaminidase A specifically breaks down fatty acid derivatives called gangliosides; these are made and biodegraded rapidly in early life as the brain develops. Patients with and carriers of Tay–Sachs can be identified by a simple blood test that measures hexosaminidase A activity.[6]
The hydrolysis of GM2-ganglioside requires three proteins. Two of them are subunits of hexosaminidase A; the third is a small glycolipid transport protein, the GM2 activator protein (GM2A), which acts as a substrate-specific cofactor for the enzyme. Deficiency in any one of these proteins leads to ganglioside storage, primarily in the lysosomes of neurons. Tay–Sachs disease (along with AB-variant GM2-gangliosidosis and Sandhoff disease) occurs because a mutation inherited from both parents deactivates or inhibits this process. Most Tay–Sachs mutations probably do not directly affect protein functional elements (e.g., the active site). Instead, they cause incorrect folding (disrupting function) or disable intracellular transport.[21]
Diagnosis[edit]
In patients with a clinical suspicion for Tay–Sachs disease, with any age of onset, the initial testing involves an enzyme assay to measure the activity of hexosaminidase in serum, fibroblasts, or leukocytes. Total hexosaminidase enzyme activity is decreased in individuals with Tay-Sachs as is the percentage of hexosaminidase A. After confirmation of decreased enzyme activity in an individual, confirmation by molecular analysis can be pursued.[22] All patients with infantile onset Tay–Sachs disease have a "cherry red" macula in the retina, easily observable by a physician using an ophthalmoscope.[6][23] This red spot is a retinal area that appears red because of gangliosides in the surrounding retinal ganglion cells. The choroidal circulation is showing through "red" in this foveal region where all retinal ganglion cells are pushed aside to increase visual acuity. Thus, this cherry-red spot is the only normal part of the retina; it shows up in contrast to the rest of the retina. Microscopic analysis of the retinal neurons shows they are distended from excess ganglioside storage.[24] Unlike other lysosomal storage diseases (e.g., Gaucher disease, Niemann–Pick disease, and Sandhoff disease), hepatosplenomegaly (liver and spleen enlargement) is not seen in Tay–Sachs.[25]
Prevention[edit]
Main article: Prevention of Tay–Sachs disease
Three main approaches have been used to prevent or reduce the incidence of Tay–Sachs:
Prenatal diagnosis. If both parents are identified as carriers, prenatal genetic testing can determine whether the fetus has inherited a defective gene copy from both parents.[26] Chorionic villus sampling (CVS), the most common form of prenatal diagnosis, can be performed between 10 and 14 weeks of gestation. Amniocentesis is usually performed at 15–18 weeks. These procedures have risks of miscarriage of 1% or less.[27][28]
Preimplantation genetic diagnosis. By retrieving the mother's eggs for in vitro fertilization, it is possible to test the embryo for the disorder prior to implantation. Healthy embryos are then selected and transferred into the mother's womb, while unhealthy embryos are discarded. In addition to Tay–Sachs disease, preimplantation genetic diagnosis has been used to prevent cystic fibrosis and sickle cell anemia among other genetic disorders.[29]
Mate selection. In Orthodox Jewish circles, the organization Dor Yeshorim carries out an anonymous screening program so that carrier couples for Tay–Sachs and other genetic disorders can avoid marriage.[30]
Management[edit]
As of 2010 there was no treatment that addressed the cause of Tay–Sachs disease or could slow its progression; people receive supportive care to ease the symptoms and extend life by reducing the chance of contracting infections.[31] Infants are given feeding tubes when they can no longer swallow.[32] In late-onset Tay–Sachs, medication (e.g., lithium for depression) can sometimes control psychiatric symptoms and seizures, although some medications (e.g., tricyclic antidepressants, phenothiazines, haloperidol, and risperidone) are associated with significant adverse effects.[19][33]
Outcomes[edit]
As of 2010, even with the best care, children with infantile Tay–Sachs disease usually die by the age of 4.[31]
Epidemiology[edit]
Founder effects occur when a small number of individuals from a larger population establish a new population. In this illustration, the original population is on the left with three possible founder populations on the right. Two of the three founder populations are genetically distinct from the original population.
Ashkenazi Jews have a high incidence of Tay–Sachs and other lipid storage diseases. In the United States, about 1 in 27 to 1 in 30 Ashkenazi Jews is a recessive carrier. The disease incidence is about 1 in every 3,500 newborn among Ashkenazi Jews.[34] French Canadians and the Cajun community of Louisiana have an occurrence similar to the Ashkenazi Jews. Irish Americans have a 1 in 50 chance of being a carrier.[citation needed] In the general population, the incidence of carriers as heterozygotes is about 1 in 300.[7] The incidence is approximately 1 in 320,000 newborns in the general population in United States.[35]
Three general classes of theories have been proposed to explain the high frequency of Tay–Sachs carriers in the Ashkenazi Jewish population:
Heterozygote advantage.[36] When applied to a particular allele, this theory posits that mutation carriers have a selective advantage, perhaps in a particular environment.[37]
Reproductive compensation. Parents who lose a child because of disease tend to "compensate" by having additional children to replace them. This phenomenon may maintain and possibly even increase the incidence of autosomal recessive disease.[38]
Founder effect. This hypothesis states that the high incidence of the 1278insTATC chromosomes[37] is the result of an elevated allele frequency[36] that existed by chance in an early founder population.[37]
Tay–Sachs disease was one of the first genetic disorders for which epidemiology was studied using molecular data. Studies of Tay–Sachs mutations using new molecular techniques such as linkage disequilibrium and coalescence analysis have brought an emerging consensus among researchers supporting the founder effect theory.[37][39][40]
History[edit]
Main article: History of Tay–Sachs disease
Waren Tay and Bernard Sachs, two physicians, described the disease's progression and provided differential diagnostic criteria to distinguish it from other neurological disorders with similar symptoms.
Both Tay and Sachs reported their first cases among Ashkenazi Jewish families. Tay reported his observations in 1881 in the first volume of the proceedings of the British Ophthalmological Society, of which he was a founding member.[41] By 1884, he had seen three cases in a single family. Years later, Bernard Sachs, an American neurologist, reported similar findings when he reported a case of "arrested cerebral development" to other New York Neurological Society members.[42][43]
Sachs, who recognized that the disease had a familial basis, proposed that the disease should be called amaurotic familial idiocy. However, its genetic basis was still poorly understood. Although Gregor Mendel had published his article on the genetics of peas in 1865, Mendel's paper was largely forgotten for more than a generation – not rediscovered by other scientists until 1899. Thus, the Mendelian model for explaining Tay–Sachs was unavailable to scientists and doctors of the time. The first edition of the Jewish Encyclopedia, published in 12 volumes between 1901 and 1906, described what was then known about the disease:[44]
It is a curious fact that amaurotic family idiocy, a rare and fatal disease of children, occurs mostly among Jews. The largest number of cases has been observed in the United States—over thirty in number. It was at first thought that this was an exclusively Jewish disease because most of the cases at first reported were between Russian and Polish Jews; but recently there have been reported cases occurring in non-Jewish children. The chief characteristics of the disease are progressive mental and physical enfeeblement; weakness and paralysis of all the extremities; and marasmus, associated with symmetrical changes in the macula lutea. On investigation of the reported cases, they found that neither consanguinity nor syphilitic, alcoholic, or nervous antecedents in the family history are factors in the etiology of the disease. No preventive measures have as yet been discovered, and no treatment has been of benefit, all the cases having terminated fatally.
Jewish immigration to the United States peaked in the period 1880–1924, with the immigrants arriving from Russia and countries in Eastern Europe; this was also a period of nativism (hostility to immigrants) in the United States. Opponents of immigration often questioned whether immigrants from southern and eastern Europe could be assimilated into American society. Reports of Tay–Sachs disease contributed to a perception among nativists that Jews were an inferior race.[43]
In 1969, Shintaro Okada and John S. O'Brien showed that Tay–Sachs disease was caused by an enzyme defect; he also proved that Tay–Sachs patients could be diagnosed by an assay of hexosaminidase A activity.[45] The further development of enzyme assays demonstrated that levels of hexosaminidases A and B could be measured in patients and carriers, allowing the reliable detection of heterozygotes. During the early 1970s, researchers developed protocols for newborn testing, carrier screening, and pre-natal diagnosis.[30][46] By the end of 1979, researchers had identified three variant forms of GM2 gangliosidosis, including Sandhoff disease and the AB variant of GM2-gangliosidosis, accounting for false negatives in carrier testing.[47]
Society and culture[edit]
Main article: Sociological and cultural aspects of Tay–Sachs disease
Since carrier testing for Tay–Sachs began in 1971, millions of Ashkenazi Jews have been screened as carriers. Jewish communities embraced the cause of genetic screening from the 1970s on. The success with Tay–Sachs disease has led Israel to become the first country that offers free genetic screening and counseling for all couples and opened discussions about the proper scope of genetic testing for other disorders in Israel.[48]
Because Tay–Sachs disease was one of the first autosomal recessive genetic disorders for which there was an enzyme assay test (prior to polymerase chain reaction testing methods), it was intensely studied as a model for all such diseases, and researchers sought evidence of a selective process. A continuing controversy is whether heterozygotes (carriers) have or had a selective advantage. The presence of four different lysosomal storage disorders in the Ashkenazi Jewish population suggests a past selective advantage for heterozygous carriers of these conditions."[39]
This controversy among researchers has reflected three debates among geneticists at large:
Dominance versus overdominance. In applied genetics (selective and agricultural breeding), this controversy has reflected the century-long debate over whether dominance or overdominance provides the best explanation for heterosis (hybrid vigor).
The classical/balance controversy. The classical hypothesis of genetic variability, often associated with Hermann Muller, maintains that most genes are of a normal wild type, and that most individuals are homozygous for that wild type, while most selection is purifying selection that operates to eliminate deleterious alleles. The balancing hypothesis, often associated with Theodosius Dobzhansky, states that heterozygosity will be common at loci, and that it frequently reflects either directional selection or balancing selection.
Selectionists versus neutralists. In theoretical population genetics, selectionists emphasize the primacy of natural selection as a determinant of evolution and of variation within a population, while neutralists favor a form of Motoo Kimura's neutral theory of molecular evolution, which emphasizes the role of genetic drift.[49]
Research directions[edit]
Enzyme replacement therapy[edit]
Enzyme replacement therapy techniques have been investigated for lysosomal storage disorders, and could potentially be used to treat Tay–Sachs as well. The goal would be to replace the nonfunctional enzyme, a process similar to insulin injections for diabetes. However, in previous studies, the HEXA enzyme itself has been thought to be too large to pass through the specialized cell layer in the blood vessels that forms the blood–brain barrier in humans.
Researchers have also tried directly instilling the deficient enzyme hexosaminidase A into the cerebrospinal fluid (CSF) which bathes the brain. However, intracerebral neurons seem unable to take up this physically large molecule efficiently even when it is directly by them. Therefore, this approach to treatment of Tay–Sachs disease has also been ineffective so far.[50]
Jacob sheep model[edit]
Tay–Sachs disease exists in Jacob sheep.[51] The biochemical mechanism for this disease in the Jacob sheep is virtually identical to that in humans, wherein diminished activity of hexosaminidase A results in increased concentrations of GM2 ganglioside in the affected animal.[52] Sequencing of the HEXA gene cDNA of affected Jacobs sheep reveal an identical number of nucleotides and exons as in the human HEXA gene, and 86% nucleotide sequence identity.[51] A missense mutation (G444R)[53] was found in the HEXA cDNA of the affected sheep. This mutation is a single nucleotide change at the end of exon 11, resulting in that exon's deletion (before translation) via splicing. The Tay–Sachs model provided by the Jacob sheep is the first to offer promise as a means for gene therapy clinical trials, which may prove useful for disease treatment in humans.[51]
Substrate reduction therapy[edit]
Other experimental methods being researched involve substrate reduction therapy, which attempts to use alternative enzymes to increase the brain's catabolism of GM2 gangliosides to a point where residual degradative activity is sufficient to prevent substrate accumulation.[54][55] One experiment has demonstrated that using the enzyme sialidase allows the genetic defect to be effectively bypassed, and as a consequence, GM2 gangliosides are metabolized so that their levels become almost inconsequential. If a safe pharmacological treatment can be developed – one that increases expression of lysosomal sialidase in neurons without other toxicity – then this new form of therapy could essentially cure the disease.[56]
Another metabolic therapy under investigation for Tay–Sachs disease uses miglustat.[57] This drug is a reversible inhibitor of the enzyme glucosylceramide synthase, which catalyzes the first step in synthesizing glucose-based glycosphingolipids like GM2 ganglioside.[58]
Increasing β-hexosaminidase A activity[edit]
As Tay–Sachs disease is a deficiency of β-hexosaminidase A, by getting a substance that increases its activity, people affected will not be deteriorating as fast or not at all. While for infantile Tay–Sachs disease, there is no β-hexosaminidase A so then the treatment would be ineffective. However, for people affected by Late-Onset Tay–Sachs disease, they still have β-hexosaminidase A. The drug Pyrimethamine has been shown to increase activity of β-hexosaminidase A.[59] However, the increased levels of β-hexosaminidase A still fall far short of the desired "10% of normal HEXA", above which the phenotypic symptoms begin to disappear.[59]
References[edit]
^ Jump up to: a b c d e f g h i j k l m n o p q r "Tay-Sachs disease". Genetics Home Reference. October 2012. Archived from the original on 13 May 2017. Retrieved 29 May 2017.
^ Jump up to: a b c d e f g h i j k "Tay Sachs Disease". NORD (National Organization for Rare Disorders). 2017. Archived from the original on 20 February 2017. Retrieved 29 May 2017.
Jump up ^ Marinetti, G. V. (2012). Disorders of Lipid Metabolism. Springer Science & Business Media. p. 205. ISBN 9781461595649. Archived from the original on 2017-11-05.
Jump up ^ Walker, Julie (2007). Tay-Sachs Disease. The Rosen Publishing Group. p. 53. ISBN 9781404206977. Archived from the original on 2017-11-05.
Jump up ^ Vogel, Friedrich; Motulsky, Arno G. (2013). Vogel and Motulsky's Human Genetics: Problems and Approaches (3 ed.). Springer Science & Business Media. p. 578. ISBN 9783662033562. Archived from the original on 2017-11-05.
^ Jump up to: a b c d e "Tay–Sachs disease Information Page". National Institute of Neurological Disorders and Stroke. 14 February 2007. Archived from the original on 29 December 2011. Retrieved 10 May 2007.
^ Jump up to: a b McKusick, Victor A; Hamosh, Ada. "Online Mendelian Inheritance in Man". United States National Institutes of Health. Archived from the original on 29 December 2011. Retrieved 24 April 2009.
Jump up ^ Specola N, Vanier MT, Goutières F, Mikol J, Aicardi J (1 January 1990). "The juvenile and chronic forms of GM2 gangliosidosis: clinical and enzymatic heterogeneity". Neurology. 40 (1): 145–150. doi:10.1212/wnl.40.1.145. PMID 2136940.
Jump up ^ Moe, P G; Benke, T A (2005). "Neurologic and Muscular Disorders". Current Pediatric Diagnosis and Treatment (17 ed.). McGraw-Hill. ISBN 978-0-07-142960-3.
Jump up ^ Rosebush PI, MacQueen GM, Clarke JT, Callahan JW, Strasberg PM, Mazurek MF (1995). "Late-onset Tay–Sachs disease presenting as catatonic schizophrenia: Diagnostic and treatment issues". Journal of Clinical Psychiatry. 56 (8): 347–53. PMID 7635850.
Jump up ^ Willner JP, Grabowski GA, Gordon RE, Bender AN, Desnick RJ (July 1981). "Chronic GM2 gangliosidosis masquerading as atypical Friedreich's ataxia: Clinical, morphologic, and biochemical studies of nine cases". Neurology. 31 (7): 787–98. doi:10.1212/wnl.31.7.787. PMID 6454083.
Jump up ^ Kaback MM (December 2000). "Population-based genetic screening for reproductive counseling: the Tay–Sachs disease model". European Journal of Pediatrics. 159 (Suppl 3): S192–S195. doi:10.1007/PL00014401. ISSN 1432-1076. PMID 11216898.
Jump up ^ Myerowitz R (1997). "Tay–Sachs disease-causing mutations and neutral polymorphisms in the Hex A gene". Human Mutation. 9 (3): 195–208. doi:10.1002/(SICI)1098-1004(1997)9:3<195::AID-HUMU1>3.0.CO;2-7. PMID 9090523.
Jump up ^ Myerowitz R, Costigan FC (15 December 1988). "The major defect in Ashkenazi Jews with Tay–Sachs disease is an insertion in the gene for the alpha-chain of beta-hexosaminidase". Journal of Biological Chemistry. 263 (35): 18587–18589. PMID 2848800. Archived from the original on 17 April 2014.
Jump up ^ McDowell GA, Mules EH, Fabacher P, Shapira E, Blitzer MG (1992). "The presence of two different infantile Tay–Sachs disease mutations in a Cajun population". American Journal of Human Genetics. 51 (5): 1071–1077. PMC 1682822  . PMID 1307230.
Jump up ^ Keats BJ, Elston RC, Andermann E (1987). "Pedigree discriminant analysis of two French Canadian Tay–Sachs families". Genetic Epidemiology. 4 (2): 77–85. doi:10.1002/gepi.1370040203. PMID 2953646.
Jump up ^ De Braekeleer M, Hechtman P, Andermann E, Kaplan F (April 1992). "The French Canadian Tay–Sachs disease deletion mutation: Identification of probable founders". Human Genetics. 89 (1): 83–87. doi:10.1007/BF00207048. PMID 1577470.
Jump up ^ Ohno K, Suzuki K (5 December 1988). "Multiple Abnormal beta-Hexosaminidase Alpha-Chain mRNAs in a Compound-Heterozygous Ashkenazi Jewish Patient with Tay–Sachs Disease" (PDF). Journal of Biological Chemistry. 263 (34): 18563–7. PMID 2973464. Archived (PDF) from the original on 26 September 2007. Retrieved 11 May 2007.
^ Jump up to: a b Kaback MM, Desnick RJ (2011). "Hexosaminidase A Deficiency". In Pagon RA, Adam MP, Ardinger HH, Bird TD, Dolan CR, Fong CT, Smith RJ, Stephens K. GeneReviews™ [Internet]. Seattle, Washington, USA: University of Washington, Seattle. PMID 20301397. Archived from the original on 2014-01-16.
Jump up ^ Korf, Bruce R (2000). Human genetics: A problem-based approach (2 ed.). Wiley-Blackwell. pp. 11–12. ISBN 0-632-04425-X.
Jump up ^ Mahuran DJ (1999). "Biochemical consequences of mutations causing the GM2 gangliosidoses". Biochimica et Biophysica Acta. 1455 (2–3): 105–138. doi:10.1016/S0925-4439(99)00074-5. PMID 10571007.
Jump up ^ Hechtman P, Kaplan F (1993). "Tay-Sachs disease screening and diagnosis: Evolving technologies". DNA and cell biology. 12 (8): 651–665. doi:10.1089/dna.1993.12.651. PMID 8397824.
Jump up ^ Tittarelli R, Giagheddu M, Spadetta V (July 1966). "Typical ophthalmoscopic picture of "cherry-red spot" in an adult with the myoclonic syndrome". The British journal of ophthalmology. 50 (7): 414–420. doi:10.1136/bjo.50.7.414. PMC 506244  . PMID 5947589.
Jump up ^ Aragão RE, Ramos RM, Pereira FB, Bezerra AF, Fernandes DN (Jul–Aug 2009). "'Cherry red spot' in a patient with Tay–Sachs disease: case report". Arq Bras Oftalmol. 72 (4): 537–9. doi:10.1590/S0004-27492009000400019. PMID 19820796.
Jump up ^ Seshadri R, Christopher R, Arvinda HR (2011). "Teaching NeuroImages: MRI in infantile Sandhoff disease". Neurology. 77 (5): e34. doi:10.1212/WNL.0b013e318227b215. PMID 21810694. Archived from the original on 29 December 2011. Retrieved 28 December 2011.
Jump up ^ Stoller D (1997). "Prenatal Genetic Screening: The Enigma of Selective Abortion". Journal of Law and Health. 12 (1): 121–140. PMID 10182027.
Jump up ^ "Chorionic Villus Sampling and Amniocentesis: Recommendations for Prenatal Counseling". United States, Center for Disease Control. Archived from the original on 14 July 2009. Retrieved 18 June 2009.
Jump up ^ Bodurtha J, Strauss JF (2012). "Genomics and perinatal care". N. Engl. J. Med. 366 (1): 64–73. doi:10.1056/NEJMra1105043. PMC 4877696  . PMID 22216843.
Jump up ^ Marik, J J (13 April 2005). "Preimplantation Genetic Diagnosis". eMedicine.com. Archived from the original on 31 January 2009. Retrieved 10 May 2007.
^ Jump up to: a b Ekstein, J; Katzenstein, H (2001). "The Dor Yeshorim story: Community-based carrier screening for Tay–Sachs disease". Tay-Sachs Disease. Advances in Genetics. 44. pp. 297–310. doi:10.1016/S0065-2660(01)44087-9. ISBN 978-0-12-017644-1. PMID 11596991.
^ Jump up to: a b Colaianni A, Chandrasekharan S, Cook-Deegan R (2010). "Impact of Gene Patents and Licensing Practices on Access to Genetic Testing and Carrier Screening for Tay–Sachs and Canavan Disease". Genetics in Medicine. 12 (4 Suppl): S5–S14. doi:10.1097/GIM.0b013e3181d5a669. PMC 3042321  . PMID 20393311.
Jump up ^ Eeg-Olofsson L, Kristensson K, Sourander P, Svennerholm L (1966). "Tay-Sachs disease. A generalized metabolic disorder". Acta Paediatrica Scand. 55 (6): 546–62. doi:10.1111/j.1651-2227.1966.tb15254.x. PMID 5972561.
Jump up ^ Shapiro BE, Hatters-Friedman S, Fernandes-Filho JA, Anthony K, Natowicz MR (12 September 2006). "Late-onset Tay–Sachs disease: Adverse effects of medications and implications for treatment". Neurology. 67 (5): 875–877. doi:10.1212/01.wnl.0000233847.72349.b6. PMID 16966555.
Jump up ^ Rozenberg R, Pereira Lda V (2001). "The frequency of Tay-Sachs disease causing mutations in the Brazilian Jewish population justifies a carrier screening program". Sao Paulo medical journal [Revista paulista de medicina]. 119 (4): 146–149. doi:10.1590/s1516-31802001000400007. PMID 11500789.
Jump up ^ GM2 Gangliosidoses - Introduction And Epidemiology Archived 2012-04-20 at the Wayback Machine. at Medscape. Author: David H Tegay. Updated: Mar 9, 2012
^ Jump up to: a b Chakravarti A, Chakraborty R (1978). "Elevated frequency of Tay–Sachs disease among Ashkenazic Jews unlikely by genetic drift alone". American Journal of Human Genetics. 30 (3): 256–261. PMC 1685578  . PMID 677122.
^ Jump up to: a b c d Frisch A, Colombo R, Michaelovsky E, Karpati M, Goldman B, Peleg L (March 2004). "Origin and spread of the 1278insTATC mutation causing Tay–Sachs disease in Ashkenazi Jews: Genetic drift as a robust and parsimonious hypothesis". Human Genetics. 114 (4): 366–376. doi:10.1007/s00439-003-1072-8. PMID 14727180.
Jump up ^ Koeslag JH, Schach SR (1984). "Tay–Sachs disease and the role of reproductive compensation in the maintenance of ethnic variations in the incidence of autosomal recessive disease". Annals of Human Genetics. 48 (3): 275–281. doi:10.1111/j.1469-1809.1984.tb01025.x. PMID 6465844.
^ Jump up to: a b Risch N, Tang H, Katzenstein H, Ekstein J (2003). "Geographic Distribution of Disease Mutations in the Ashkenazi Jewish Population Supports Genetic Drift over Selection". American Journal of Human Genetics. 72 (4): 812–822. doi:10.1086/373882. PMC 1180346  . PMID 12612865.
Jump up ^ Slatkin M (2004). "A Population-Genetic Test of Founder Effects and Implications for Ashkenazi Jewish Diseases". American Journal of Human Genetics. 75 (2): 282–293. doi:10.1086/423146. PMC 1216062  . PMID 15208782.
Jump up ^ Tay, Waren (1881). "Symmetrical changes in the region of the yellow spot in each eye of an infant". Transactions of the Ophthalmological Society. 1: 55–57.
Jump up ^ Sachs, Bernard (1887). "On arrested cerebral development with special reference to cortical pathology". Journal of Nervous Mental Disease. 14 (9): 541–554. doi:10.1097/00005053-188714090-00001.
^ Jump up to: a b Reuter, Shelley Z (Summer 2006). "The Genuine Jewish Type: Racial Ideology and Anti-Immigrationism in Early Medical Writing about Tay–Sachs Disease". The Canadian Journal of Sociology. 31 (3): 291–323. doi:10.1353/cjs.2006.0061. Archived from the original on 2016-03-04.
Jump up ^ "Amaurotic Idiocy". The Jewish Encyclopedia. New York: Funk and Wagnalls. 1901–1906. Archived from the original on 29 December 2011. Retrieved 7 March 2009.
Jump up ^ Okada S, O'Brien JS (1969). "Tay–Sachs disease: Generalized absence of a beta-D-N-acetylhexosaminidase component". Science. 165 (3894): 698–700. Bibcode:1969Sci...165..698O. doi:10.1126/science.165.3894.698. PMID 5793973.
Jump up ^ O'Brien JS, Okada S, Chen A, Fillerup DL (1970). "Tay–Sachs disease: Detection of heterozygotes and homozygotes by serum hexaminidase assay". New England Journal of Medicine. 283 (1): 15–20. doi:10.1056/NEJM197007022830104. PMID 4986776.
Jump up ^ O'Brien, John S (1983). "The Gangliosidoses". In Stanbury, J B; et al. The Metabolic Basis of Inherited Disease. New York: McGraw Hill. pp. 945–969.
Jump up ^ Sagi M (1998). "Ethical aspects of genetic screening in Israel". Science in Context. 11 (3–4): 419–429. doi:10.1017/s0269889700003112. PMID 15168671.
Jump up ^ Kimura, Motoo (1983). The Neutral Theory of Molecular Evolution. Cambridge: Cambridge University Press. ISBN 0-521-23109-4.
Jump up ^ Matsuoka K, Tamura T, Tsuji D, Dohzono Y, Kitakaze K, Ohno K, Saito S, Sakuraba H, Itoh K (14 October 2011). "Therapeutic Potential of Intracerebroventricular Replacement of Modified Human β-Hexosaminidase B for GM2 Gangliosidosis". Molecular Therapy. Nature. 19 (6): 1017–1024. doi:10.1038/mt.2011.27. PMC 3129794  . PMID 21487393. Archived from the original on 21 August 2014.
^ Jump up to: a b c Torres PA, Zeng BJ, Porter BF, Alroy J, Horak F, Horak J, Kolodny EH (2010). "Tay–Sachs disease in Jacob sheep". Molecular Genetics and Metabolism. 101 (4): 357–363. doi:10.1016/j.ymgme.2010.08.006. ISSN 1096-7192. PMID 20817517.
Jump up ^ Porter BF, Lewis BC, Edwards JF, Alroy J, Zeng BJ, Torres PA, Bretzlaff KN, Kolodny EH (2011). "Pathology of GM2 Gangliosidosis in Jacob Sheep". Veterinary Pathology. 48 (3): 807–813. doi:10.1177/0300985810388522. ISSN 0300-9858. PMID 21123862.
Jump up ^ Kolodny E, Horak F, Horak J (2011). "Jacob sheep breeders find more Tay–Sachs carriers". ALBC Newsletter. Pittsboro, North Carolina, USA: American Livestock Breeds Conservancy. Archived from the original on 29 December 2011. Retrieved 5 May 2011.
Jump up ^ Platt FM, Neises GR, Reinkensmeier G, Townsend MJ, Perry VH, Proia RL, Winchester B, Dwek RA, Butters TD (1997). "Prevention of lysosomal storage in Tay–Sachs mice treated with N-butyldeoxynojirimycin". Science. American Association for the Advancement of Science. 276 (5311): 428–431. doi:10.1126/science.276.5311.428. PMID 9103204.
Jump up ^ Lachmann RH, Platt FM (2001). "Substrate reduction therapy for glycosphingolipid storage disorders". Expert Opinion on Investigational Drugs. 10 (3): 455–466. doi:10.1517/13543784.10.3.455. PMID 11227045.
Jump up ^ Igdoura SA, Mertineit C, Trasler JM, Gravel RA (1999). "Sialidase-mediated depletion of GM2 ganglioside in Tay–Sachs neuroglia cells". Human Molecular Genetics. Oxford University Press. 8 (6): 1111–1116. doi:10.1093/hmg/8.6.1111. PMID 10332044.
Jump up ^ "Pharmacokinetics, Safety and Tolerability of Zavesca (Miglustat) in Patients With Infantile Onset Gangliosidosis: Single and Steady State Oral Doses". 5 May 2008. Archived from the original on 13 February 2012. Retrieved 10 April 2012.
Jump up ^ Kolodny EH, Neudorfer O, Gianutsos J, Zaroff C, Barnett N, Zeng BJ, Raghavan S, Torres P, Pastores GM (2004). "Late-onset Tay–Sachs disease: Natural history and treatment with OGT 918 (Zavesca™)". Journal of Neurochemistry. 90 (S1): 54–55. doi:10.1111/j.1471-4159.2004.02650_.x. ISSN 0022-3042.
^ Jump up to: a b Osher E, Fattal-Valevski A, Sagie L, Urshanski N, Amir-Levi Y, Katzburg S, Peleg L, Lerman-Sagie T, Zimran A, Elstein D, Navon R, Stern N, Valevski A (March 2011). "Pyrimethamine increases β-hexosaminidase A activity in patients with Late Onset Tay Sachs". Mol. Genet. Metab. Molecular Genetics and Metabolism. 102 (3): 356–63. doi:10.1016/j.ymgme.2010.11.163. PMID 21185210.
External links[edit]
Classification
V · T · D
ICD-10: E75.0
ICD-9-CM: 330.1
OMIM: 272800 272750
MeSH: D013661
DiseasesDB: 12916
External resources
MedlinePlus: 001417
eMedicine: ped/3016
Patient UK: Tay–Sachs disease

Wikimedia Commons has media related to Tay–Sachs disease.
GeneReviews/NCBI/NIH/UW entry on hexosaminidase A deficiency, Tay–Sachs disease
NINDS Tay–Sachs Disease Information Page
Tay–Sachs disease at NLM Genetics Home Reference
Tay–Sachs on NCBI
[hide]
v
t
e
(LSD) Inborn error of lipid metabolism: lipid storage disorders (E75, 272.7–272.8)
Sphingolipidoses
(to ceramide)
From ganglioside
(gangliosidoses)
Ganglioside: GM1 gangliosidoses
GM2 gangliosidoses (Sandhoff disease
Tay–Sachs disease
AB variant)
From globoside
Globotriaosylceramide: Fabry's disease
From sphingomyelin
Sphingomyelin: phospholipid: Niemann–Pick disease (SMPD1-associated
type C)
Glucocerebroside: Gaucher's disease
From sulfatide
(sulfatidoses
leukodystrophy)
Sulfatide: Metachromatic leukodystrophy
Multiple sulfatase deficiency
Galactocerebroside: Krabbe disease
To sphingosine
Ceramide: Farber disease
NCL
Infantile
Jansky–Bielschowsky disease
Batten disease
Other
Cerebrotendineous xanthomatosis
Cholesteryl ester storage disease (Lysosomal acid lipase deficiency/Wolman disease)
Sea-blue histiocytosis
Retrieved from "https://en.wikipedia.org/w/index.php?title=Tay–Sachs_disease&oldid=831458769"
Categories:
Autosomal recessive disorders
Lipid storage disorders
Rare diseases
Ashkenazi Jews topics
Neurodegenerative disorders
Neurological disorders in children
Tay–Sachs disease
Lysosomal storage diseases
Congenital disorders
Hidden categories:
Webarchive template wayback links
Infobox medical condition (new)
All articles with unsourced statements
Articles with unsourced statements from April 2014
RTT
Navigation menu
Personal tools
Not logged in
Talk
Contributions
Create account
Log in
Namespaces
Article
Talk
Variants
Views
Read
Edit
View history
More
Search
Navigation
Main page
Contents
Featured content
Current events
Random article
Donate to Wikipedia
Wikipedia store
Interaction
Help
About Wikipedia
Community portal
Recent changes
Contact page
Tools
What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Wikidata item
Cite this page
Print/export
Create a book
Download as PDF
Printable version
In other projects
Wikimedia Commons
Languages
العربية
Català
Čeština
Deutsch
Eesti
Español
فارسی
Français
Gaeilge
Íslenska
Italiano
עברית
ქართული
Magyar
മലയാളം
Bahasa Melayu
Nederlands
日本語
ଓଡ଼ିଆ
Polski
Português
Русский
Simple English
Slovenčina
Slovenščina
Suomi
Українська
中文
19 more
Edit links
This page was last edited on 20 March 2018, at 18:18.
Text is available under the Creative Commons Attribution-ShareAlike License; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.
Privacy policy
About Wikipedia
Disclaimers
Contact Wikipedia
Developers
Cookie statement
Mobile view
Enable previews

values: mw-page-base noprint

values: mw-head-base noprint

values: firstHeading firstHeading en

values: siteSub noprint

values: jump-to-nav mw-jump

value: th

attrs: colspan style

value: tr

value: sup

value: td

attrs: alt src width height data-file-width data-file-height

values:
/wiki/Autosomal_recessive
mw-redirect
Autosomal recessive

values:
/wiki/Diagnostic_method
mw-redirect
Diagnostic method

values:
/wiki/Hexosaminidase_A
mw-redirect
Hexosaminidase A

values:
/wiki/Leigh_syndrome
mw-redirect
Leigh syndrome

values:
/wiki/Neuronal_ceroid_lipofuscinoses
mw-redirect
Neuronal ceroid lipofuscinoses

values:
/wiki/Supportive_care
mw-redirect
Supportive care

values:
/wiki/Genetic_mutation
mw-redirect
Genetic mutation

values:
/wiki/Chromosome_15_(human)
mw-redirect
Chromosome 15 (human)

values:
/wiki/Beta-hexosamidase_A
mw-redirect
Beta-hexosamidase A

values:
/wiki/GM2_ganglioside
mw-redirect
GM2 ganglioside

values:
/wiki/French_Canadian
mw-redirect
French Canadian

values:
/wiki/Genetic_deterioration
mw-redirect
Genetic deterioration

values:
/wiki/Hydrolytic_enzyme
mw-redirect
Hydrolytic enzyme

values:
/wiki/Gaucher_disease
mw-redirect
Gaucher disease

values:
/wiki/Prenatal_diagnosis
mw-redirect
Prenatal diagnosis

values:
/wiki/In_vitro_fertilization
mw-redirect
In vitro fertilization

values:
/wiki/Sickle_cell_anemia
mw-redirect
Sickle cell anemia

values:
/wiki/Ashkenazi_Jew
mw-redirect
Ashkenazi Jew

values:
/wiki/Irish_American
mw-redirect
Irish American

values: This claim needs references to reliable sources. (April 2014)

values:
noprint Inline-Template Template-Fact
white-space:nowrap;

values:
/wiki/Coalescence_(genetics)
mw-redirect
Coalescence (genetics)

values: History of the Jews in the United States

values: Sociological and cultural aspects of Tay–Sachs disease

values:
/wiki/Selection_(biology)
mw-redirect
Selection (biology)

values:
/wiki/Lysosomal_storage_disorders
mw-redirect
Lysosomal storage disorders

values:
/wiki/Ashkenazi_Jewish
mw-redirect
Ashkenazi Jewish

values:
/wiki/Dominance_versus_overdominance
mw-redirect
Dominance versus overdominance

values:
/wiki/Purifying_selection
mw-redirect
Purifying selection

values:
/wiki/Neutral_allele_theory
mw-redirect
Neutral allele theory

values: Edit section: Enzyme replacement therapy

values:
/wiki/Jacob_(sheep)
mw-redirect
Jacob (sheep)

values:
/wiki/Splicing_(genetics)
mw-redirect
Splicing (genetics)

values:
/wiki/Clinical_trials
mw-redirect
Clinical trials

values: Edit section: Substrate reduction therapy

values:
/wiki/Glucosylceramide_synthase
mw-redirect
Glucosylceramide synthase

values: Edit section: Increasing β-hexosaminidase A activity

values: National Institute of Neurological Disorders and Stroke

values:
nofollow
external text
http://omim.org/entry/272800

values:
nofollow
external text
//doi.org/10.1212%2Fwnl.40.1.145

values:
/wiki/PubMed_Identifier
mw-redirect
PubMed Identifier

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/2136940

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/7635850

values:
nofollow
external text
//doi.org/10.1212%2Fwnl.31.7.787

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/6454083

values:
nofollow
external text
//doi.org/10.1007%2FPL00014401

values:
nofollow
external text
//www.worldcat.org/issn/1432-1076

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/11216898

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/9090523

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/2848800

attrs: alt src title width height srcset data-file-width data-file-height

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/1307230

values:
nofollow
external text
//doi.org/10.1002%2Fgepi.1370040203

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/2953646

values:
nofollow
external text
//doi.org/10.1007%2FBF00207048

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/1577470

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/2973464

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/20301397

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/10571007

values:
nofollow
external text
//doi.org/10.1089%2Fdna.1993.12.651

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/8397824

values:
nofollow
external text
//doi.org/10.1136%2Fbjo.50.7.414

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/5947589

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/19820796

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/21810694

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/10182027

values:
nofollow
external text
//doi.org/10.1056%2FNEJMra1105043

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/22216843

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/11596991

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/20393311

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/5972561

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16966555

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/11500789

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/677122

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/14727180

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/6465844

values:
nofollow
external text
//doi.org/10.1086%2F373882

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/12612865

values:
nofollow
external text
//doi.org/10.1086%2F423146

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/15208782

values:
nofollow
external text
//doi.org/10.1353%2Fcjs.2006.0061

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/5793973

values:
nofollow
external text
//doi.org/10.1056%2FNEJM197007022830104

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/4986776

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/15168671

values:
nofollow
external text
//doi.org/10.1038%2Fmt.2011.27

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/21487393

values:
nofollow
external text
//doi.org/10.1016%2Fj.ymgme.2010.08.006

values:
nofollow
external text
//www.worldcat.org/issn/1096-7192

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/20817517

values:
nofollow
external text
//www.worldcat.org/issn/0300-9858

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/21123862

values: American Association for the Advancement of Science

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/9103204

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/11227045

values:
nofollow
external text
//doi.org/10.1093%2Fhmg%2F8.6.1111

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/10332044

values:
nofollow
external text
//www.worldcat.org/issn/0022-3042

values:
nofollow
external text
//doi.org/10.1016%2Fj.ymgme.2010.11.163

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/21185210

values: International Statistical Classification of Diseases and Related Health Problems

values:
nofollow
external text
https://omim.org/entry/272800

values:
nofollow
external text
https://omim.org/entry/272750

values: width:22em;width:100%; margin:0 0 0.5em 0;

values:
/wiki/U.S._National_Library_of_Medicine
mw-redirect
U.S. National Library of Medicine

values:
/wiki/Inborn_error_of_metabolism
mw-redirect
Inborn error of metabolism

values: ICD-10 Chapter IV: Endocrine, nutritional and metabolic diseases

values: List of ICD-9 codes 240–279: endocrine, nutritional and metabolic diseases, and immunity disorders

values: Infantile neuronal ceroid lipofuscinosis

values:
/wiki/Cholesteryl_ester_storage_disease
mw-redirect
Cholesteryl ester storage disease

values:
/wiki/Wolman_disease
mw-redirect
Wolman disease

values: nowraplinks collapsible autocollapse navbox-inner

values: Category:Neurological disorders in children

values: Category:Webarchive template wayback links

values: Category:Infobox medical condition (new)

values: Category:All articles with unsourced statements

values: Category:Articles with unsourced statements from April 2014

values: Discussion about edits from this IP address [ctrl-alt-n]

values: A list of edits made from this IP address [ctrl-alt-y]

values: You are encouraged to create an account and log in; however, it is not mandatory

values: You're encouraged to log in; however, it's not mandatory. [ctrl-alt-o]

values:
/wiki/Tay%E2%80%93Sachs_disease
View the content page [ctrl-alt-c]
c

values: Discussion about the content page [ctrl-alt-t]

values: p-namespaces navigation vectorTabs p-namespaces-label

values:
p-variants
navigation
vectorMenu emptyPortlet
p-variants-label

values: Past revisions of this page [ctrl-alt-h]

values: p-views navigation vectorTabs p-views-label

values:
p-cactions
navigation
vectorMenu emptyPortlet
p-cactions-label

values:
mw-wiki-logo
/wiki/Main_Page
Visit the main page

values:
/wiki/Main_Page
Visit the main page [ctrl-alt-z]
z

values: Featured content – the best of Wikipedia

values: Find background information on current events

values:
/wiki/Special:Random
Load a random article [ctrl-alt-x]
x

values: portal navigation p-navigation p-navigation-label

values: Guidance on how to use and edit Wikipedia

values: About the project, what you can do, where to find things

values: A list of recent changes in the wiki [ctrl-alt-r]

values: portal navigation p-interaction p-interaction-label

values: List of all English Wikipedia pages containing links to this page [ctrl-alt-j]

values: Recent changes in pages linked from this page [ctrl-alt-k]

values:
/wiki/Wikipedia:File_Upload_Wizard
Upload files [ctrl-alt-u]
u

values: A list of all special pages [ctrl-alt-q]

values: Permanent link to this revision of the page

values: Link to connected data repository item [ctrl-alt-g]

values: Printable version of this page [ctrl-alt-p]

values: portal navigation p-wikibase-otherprojects p-wikibase-otherprojects-label

values: داء تاي ساكس – Arabic

values:
interlanguage-link interwiki-ca
display: none;

values:
interlanguage-link interwiki-cs
display: none;

values:
interlanguage-link interwiki-et
display: none;

values: بیماری تی-سکس – Persian

values:
interlanguage-link interwiki-fa
display: none;

values:
interlanguage-link interwiki-ga
display: none;

values:
interlanguage-link interwiki-is
display: none;

values:
interlanguage-link interwiki-it
display: none;

values: טאי זקס – Hebrew

values:
interlanguage-link interwiki-he
display: none;

values: ტეა-საქსის სინდრომი – Georgian

values:
interlanguage-link interwiki-ka
display: none;

values:
interlanguage-link interwiki-hu
display: none;

values: ടേ-സാക്സ് രോഗം – Malayalam

values:
interlanguage-link interwiki-ml
display: none;

values:
https://ms.wikipedia.org/wiki/Tay-Sachs
Tay-Sachs – Malay
ms
ms
interlanguage-link-target

values:
interlanguage-link interwiki-nl
display: none;

values: テイ＝サックス病 – Japanese

values: ଟେ-ସାକ୍‌ସ ଡିଜିଜ – Odia

values:
interlanguage-link interwiki-or
display: none;

values:
interlanguage-link interwiki-pl
display: none;

values: Болезнь Тея — Сакса – Russian

values:
interlanguage-link interwiki-simple
display: none;

values:
interlanguage-link interwiki-sk
display: none;

values:
interlanguage-link interwiki-sl
display: none;

values:
interlanguage-link interwiki-fi
display: none;

values: Хвороба Тея — Сакса – Ukrainian

values:
interlanguage-link interwiki-uk
display: none;

values:
https://zh.wikipedia.org/wiki/Tay-sachs
Tay-sachs – Chinese
zh
zh
interlanguage-link-target

values: All languages (initial selection from common choices by you and others)

values: /static/images/wikimedia-button-1.5x.png 1.5x, /static/images/wikimedia-button-2x.png 2x

values: /static/images/poweredby_mediawiki_132x47.png 1.5x, /static/images/poweredby_mediawiki_176x62.png 2x

values:
suggestions
display: none; font-size: 13px;

values: mediawiki ltr sitedir-ltr mw-hide-empty-elt ns-0 ns-subject page-Tay–Sachs_disease rootpage-Tay–Sachs_disease skin-vector action-view